[go: up one dir, main page]

WO2000062808A3 - Cobalamin conjugates useful as antitumor agents - Google Patents

Cobalamin conjugates useful as antitumor agents Download PDF

Info

Publication number
WO2000062808A3
WO2000062808A3 PCT/US2000/010100 US0010100W WO0062808A3 WO 2000062808 A3 WO2000062808 A3 WO 2000062808A3 US 0010100 W US0010100 W US 0010100W WO 0062808 A3 WO0062808 A3 WO 0062808A3
Authority
WO
WIPO (PCT)
Prior art keywords
antitumor agents
conjugates useful
compounds
cobalamin conjugates
cobalamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010100
Other languages
French (fr)
Other versions
WO2000062808A2 (en
WO2000062808A8 (en
Inventor
Douglas A Collins
Henricus P C Hogenkamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
University of Minnesota Twin Cities
University of Minnesota System
Original Assignee
Mayo Foundation for Medical Education and Research
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002370419A priority Critical patent/CA2370419A1/en
Priority to KR1020017013054A priority patent/KR20020032421A/en
Priority to MXPA01010395A priority patent/MXPA01010395A/en
Priority to AU42437/00A priority patent/AU4243700A/en
Priority to EP00922213A priority patent/EP1171162A2/en
Priority to JP2000611944A priority patent/JP2002542207A/en
Application filed by Mayo Foundation for Medical Education and Research, University of Minnesota Twin Cities, University of Minnesota System filed Critical Mayo Foundation for Medical Education and Research
Publication of WO2000062808A2 publication Critical patent/WO2000062808A2/en
Publication of WO2000062808A3 publication Critical patent/WO2000062808A3/en
Anticipated expiration legal-status Critical
Publication of WO2000062808A8 publication Critical patent/WO2000062808A8/en
Priority to US10/777,820 priority patent/US7468432B2/en
Priority to US12/266,763 priority patent/US20090060837A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/06—Cobalt compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.
PCT/US2000/010100 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents Ceased WO2000062808A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020017013054A KR20020032421A (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents
MXPA01010395A MXPA01010395A (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents.
AU42437/00A AU4243700A (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents
EP00922213A EP1171162A2 (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents
JP2000611944A JP2002542207A (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents
CA002370419A CA2370419A1 (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents
US10/777,820 US7468432B2 (en) 1999-04-16 2004-02-12 Cobalamin conjugates useful as antitumor agents
US12/266,763 US20090060837A1 (en) 1999-04-16 2008-11-07 Cobalamin conjugates useful as antitumor agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12973399P 1999-04-16 1999-04-16
US60/129,733 1999-04-16
US15987399P 1999-10-15 1999-10-15
US60/159,873 1999-10-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/690,197 Continuation-In-Part US6806363B1 (en) 1999-04-16 2000-10-16 Cobalamin conjugates useful as antitumor agents
US10/777,820 Continuation-In-Part US7468432B2 (en) 1999-04-16 2004-02-12 Cobalamin conjugates useful as antitumor agents

Publications (3)

Publication Number Publication Date
WO2000062808A2 WO2000062808A2 (en) 2000-10-26
WO2000062808A3 true WO2000062808A3 (en) 2001-02-22
WO2000062808A8 WO2000062808A8 (en) 2001-12-06

Family

ID=26827868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010100 Ceased WO2000062808A2 (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents

Country Status (7)

Country Link
EP (1) EP1171162A2 (en)
JP (1) JP2002542207A (en)
KR (1) KR20020032421A (en)
AU (1) AU4243700A (en)
CA (1) CA2370419A1 (en)
MX (1) MXPA01010395A (en)
WO (1) WO2000062808A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141233B2 (en) 1995-11-13 2006-11-28 Mayo Foundation For Medical Education And Research Radionuclide labeling of vitamin B12 and coenzymes thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
MXPA02003772A (en) 1999-10-15 2005-04-28 Mayo Foundation Cobalamin conjugates useful as imaging and therapeutic agents.
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
WO2001028592A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
AU2002239719A1 (en) * 2000-10-25 2002-06-03 Mayo Foundation For Medical Education And Research Transcobalamin receptor binding conjugates for neutron capture therapy
EP1334114A2 (en) 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US20030144198A1 (en) * 2001-09-28 2003-07-31 Collins Douglas A. Coadministration of transport protein with conjugated cobalamin to deliver agents
SE0203823D0 (en) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel Compounds
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
WO2005061527A1 (en) * 2003-12-22 2005-07-07 Solidago Ag Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation
CN112442095B (en) * 2020-12-01 2022-07-22 上海科黛生物科技有限公司 Refining method of vitamin B12 and application of obtained product

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009160A1 (en) * 1990-11-07 1992-05-29 Tau Systems Corporation A secure system for activating personal computer software at remote locations
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
WO2000045857A2 (en) * 1999-02-01 2000-08-10 Schering Aktiengesellschaft Metal macrocycles for two-step forms of radiotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US6315978B1 (en) * 1996-08-27 2001-11-13 University Of Utah, Research Foundation Bioconjugates and delivery of bioactive agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009160A1 (en) * 1990-11-07 1992-05-29 Tau Systems Corporation A secure system for activating personal computer software at remote locations
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
WO2000045857A2 (en) * 1999-02-01 2000-08-10 Schering Aktiengesellschaft Metal macrocycles for two-step forms of radiotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOGENKAMP, H. P. C. ET AL: "Synthesis and characterization of nido-carborane- cobalamin conjugates", NUCL. MED. BIOL. (2000), 27(1), 89-92, XP002148452 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141233B2 (en) 1995-11-13 2006-11-28 Mayo Foundation For Medical Education And Research Radionuclide labeling of vitamin B12 and coenzymes thereof

Also Published As

Publication number Publication date
WO2000062808A2 (en) 2000-10-26
KR20020032421A (en) 2002-05-03
JP2002542207A (en) 2002-12-10
MXPA01010395A (en) 2004-08-12
EP1171162A2 (en) 2002-01-16
AU4243700A (en) 2000-11-02
WO2000062808A8 (en) 2001-12-06
CA2370419A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
UA103758C2 (en) Insulin-oligomer conjugates, formulations and uses thereof
EP2357006A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
MY125978A (en) Admantane derivatives
HUP0204372A3 (en) Pharmaceutical compositions providing enhanced drug concentrations
WO2000062808A8 (en) Cobalamin conjugates useful as antitumor agents
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
WO1999015541A3 (en) Use of a pentopyranosyl nucleoside for producing an electronic component, and conjugates of said pentopyranosyl nucleoside
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
TR200002541T2 (en) Pharmaceutical composition of topiramate
EP1017675A4 (en) Highly lipophilic camptothecin derivatives
AU2002215904A1 (en) Compounds with a branched linker
WO2005041881A3 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
DE60029084D1 (en) NEW DEPSIPEPTID CONNECTION
ATE338567T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING ACTIVE INGREDIENTS SUITABLE FOR UNAUTHORIZED ADMINISTRATION
EP1594513A4 (en) Carbohydrate conjugates to prevent abuse of controlled substances
WO2007092299A3 (en) Targeted conjugates and radiation
AU1373197A (en) Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents
WO2000014119A3 (en) Bifunctional antibodies and their use in targeting anti-tumour agents
AU8028600A (en) Methods, pharmaceutical and therapeutic compositions for administering adenosine
WO2000072802A3 (en) Water soluble multi-biotin-containing compounds
WO2002060420A3 (en) Utilization of a claudin-4 ligand and conjugates thereof in the therapy and diagnosis of tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1020017013054

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 611944

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010395

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2370419

Country of ref document: CA

Ref document number: 2370419

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000922213

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWP Wipo information: published in national office

Ref document number: 2000922213

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000922213

Country of ref document: EP